^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation + EGFR amplification

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2ms
    Genetic mutation patterns among glioblastoma patients in the Taiwanese population - insights from a single institution retrospective study. (PubMed, Cancer Gene Ther)
    In Taiwanese GBM patients, bevacizumab usage is linked to improved survival rates, affirming its safety and effectiveness...TP53 mutations are associated with enhanced survival, but their functional implications necessitate detailed exploration. This study pioneers genetic analysis in Taiwanese GBM patients using NGS, advancing our understanding of their genetic landscape.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CHEK2 (Checkpoint kinase 2)
    |
    TP53 mutation • EGFR mutation • CHEK2 mutation • IDH1 R132H • EGFR mutation + EGFR amplification • IDH1 R132
    |
    Avastin (bevacizumab)
    over1year
    Anti-tumor activity of BDTX-1535, an irreversible CNS penetrant inhibitor of multiple EGFR extracellular domain alterations, in preclinical glioblastoma models (AACR-NCI-EORTC 2022)
    RWE findings demonstrate a heterogeneous EGFR mutational profile in GBM patients, with persistent prevalence over time. BDTX-1535 is currently in a phase I clinical study (NCT05256290).
    Preclinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR amplification • EGFR wild-type • EGFR mutation + EGFR amplification • EGFRvIII expression
    |
    Tempus xT Assay
    |
    BDTX-1535